Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 223

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Acute myeloid leukaemia

Not recruiting

Study of Relatlimab, Nivolumab, and 5-Azacytidine for Acute Myeloid Leukemia in Patients Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Oesophageal carcinoma+3

Not recruiting

Study on Changes in [18F]F-AraG Uptake After Radiotherapy in Patients with Non-Small Cell Lung Cancer, Melanoma, Breast Cancer, and Esophageal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nelarabine
  • Sponsor:Amsterdam UMC Stichting

Leukaemia+1

Not recruiting

Study on the Safety of ATreg Cells for Patients with Leukemia After Stem Cell Transplant to Reduce Graft vs Host Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Cd4+ And Cd25+ T Lymphocytes Ex Vivo Incubated With Gp120
  • Sponsor:ActiTrexx GmbH

Pancreatic carcinoma metastatic

Not recruiting

Study on the Effects of VCN-01 with Nab-Paclitaxel and Gemcitabine for Patients with Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Genetically modified human adenovirus encoding human PH20 hyaluronidase
  • Sponsor:Theriva Biologics S.L.

Metastatic renal cell carcinoma

Not recruiting

Study of Axitinib and Pembrolizumab for Patients with Advanced or Metastatic Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Centre Leon Berard

Neoplasm malignant+1

Not recruiting

Study of ACP-017 and Pembrolizumab for Patients with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ACP-017
  • Sponsor:Ascendis Pharma Oncology Division A/S

Follicular lymphoma

Not recruiting

Study of Mosunetuzumab and Zanubrutinib for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:Fondazione Italiana Linfomi Ets

Gastrointestinal stromal tumour

Not recruiting

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Region Skane

Study on the Safety and Effects of TNG908 in Patients with Advanced or Metastatic Solid Tumors Missing the MTAP Gene

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dobutamine Hydrochloride
  • Sponsor:Tango Therapeutics Inc.

Chronic myeloid leukaemia

Not recruiting

Study of Ponatinib for Patients with Resistant Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ponatinib
  • Sponsor:Takeda Development Center Americas Inc.

EGFR gene mutation+1

Not recruiting

Study on Amivantamab, Lazertinib, and Bevacizumab for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer After Treatment Progression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:ETOP IBCSG Partners Foundation

Sarcoma

Not recruiting

Study on Advanced Soft-Tissue Sarcoma: Testing Futibatinib and Drug Combination for Patients with Unresectable or Metastatic Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capmatinib
  • Sponsor:Inserm

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.